DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Meta Expands AI Training With Employee Activity Tracking Tools 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
LOS ANGELES, April 04, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Aratana Therapeutics, Inc. (“Aratana” or the “Company”) (Nasdaq:PETX) concerning possible violations of federal securities laws between March 16, 2015 and February 3, 2017 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm by the April 7, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, Aratana made false and/or misleading statements and/or failed to disclose: that the Company did not have manufacturing contracts in place sufficient to support manufacturing of its appetite stimulation drug ENTYCE at a commercial scale; ENTYCE was not likely to be commercially available until late 2017; the Company had misled investors with respect to the likely timeline for a commercial launch of ENTYCE; and that as a result of the above, Aratana’s public statements were materially false and misleading at all relevant times.
On February 6, 2017, the Company disclosed that the Center for Veterinary Medicine requested more information about ENTYCE. Aratana told investors that it “now anticipates that ENTYCE . . . will be commercially available by late 2017” and that the CVM's demand was “in connection with the Company's post-approval supplement request to transfer the manufacturing of ENTYCE to a new vendor in order to produce ENTYCE at a commercial scale.” When this news was announced to the public, the value of Aratana stock declined, causing investors severe harm.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
